GSK & Boehringer Ingelheim Expansions & Investments
In response to escalating challenges in pharmaceutical manufacturing, the British Generic Manufacturers Association notes a 100% surge in shortages compared to January 2022. Issues include manufacturing complexities, supply chain delays, and unforeseen demand.
Investments strengthening global manufacturing presence
British pharmaceutical leader GSK is amplifying its manufacturing footprint by investing £67m in a Montrose, Scotland factory. Regis Simard, Head of Global Supply Chain at GSK, emphasises the significance of UK sites within the global network:
“GSK has a proud heritage of making innovative medicines in the UK,” Simard says.
“Our six UK manufacturing sites, including Montrose, are an important part of our global manufacturing network and we’re continuously investing in science, technology and skills to deliver medicines faster and more efficiently.”
German pharmaceutical giant Boehringer Ingelheim is inaugurating a new manufacturing base in Greece with a €120m investment. The move, attended by Greek Prime Minister Kyriakos Mitsotakis, aims to create 110 jobs and boost Jardiance exports. Hubertus von Baumbach, Chairman of the Board of Managing Directors at Boehringer Ingelheim, expresses gratitude for Greece's continuous support, marking a strategic goal to position the country as a pharmaceutical industry reference point.
“I am delighted to once again visit this plant which, as we have heard, produces some of the most innovative antidiabetic medicines and to see the excellent organisation as well as the high level of expertise and professionalism of the staff,” said the Prime Minister. “I am also very pleased with the progress that the company has made.”
Mitsotakis thanked Boehringer Ingelheim for its continuous trust in Greece.
“It is a strategic goal that we as a state also embrace: to make our country a reference point for the pharmaceutical industry.”
“We have been present in Greece since 1966, and have gradually expanded our operations in the country,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors at Boehringer Ingelheim. “This expansion investment will bring some of our most innovative therapies to an increasing number of patients globally.”
**************
Make sure you check out the latest industry news and insights at Healthcare Digital and also sign up to our global conference series - Tech & AI LIVE 2024
**************
Healthcare Digital is a BizClik brand
*************
